chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Malaise, Myalgia, Nausea
Clinical narrative: Fatigue; Headache; Muscle pain; Nausea; Feeling unwell in general; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 24Mar2021 at 15:15 (at the age of 60-years-old), as a single dose for COVID-19 immunisation. The patient's medical history was not reported. The patient was allergic to CEFTIN. The patient received unspecified medications within two weeks of vaccination. The patient did not receive any other vaccines within the 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 11:00, the patient experienced fatigue, headache, muscle pain, nausea and feeling unwell in general. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the fatigue, headache, muscle pain, nausea and feeling unwell in general were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Lymphadenopathy, Myalgia
Clinical narrative: Muscle aches; Low grade fever (100.1 for 24 hours); Swollen lymph nodes; Chills; headache; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN8720), via an unspecified route of administration in the left arm on 24Mar2021 at 11:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis and migraines. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. Concomitant medications included hydroxychloroquine (MANUFACTURER UNKNOWN), vitamins (MANUFACTURER UNKNOWN), ethinylestradiol; ferrous fumarate; norethisterone acetate (LO LOESTRIN FE) and escitalopram oxalate (LEXAPRO), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration in the left arm on 03Mar2021 at 14:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Mar2021 at 18:00, the patient experienced muscle aches, low grade fever (100.1 for 24 hours), swollen lymph nodes, chills and headache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab test on 09Mar2021 and 16Mar2021 which included Covid PCR test via nasal swab and the test result was negative. The patient did not receive any treatment for the events muscle aches, low grade fever (100.1 for 24 hours), swollen lymph nodes, chills and headache. The clinical outcomes of the events muscle aches, low grade fever (100.1 for 24 hours), swollen lymph nodes, chills and headache were recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test
Clinical narrative: Muscle aches; Low grade fever (100.1 for 24 hours); Swollen lymph nodes; Chills; headache; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN8720), via an unspecified route of administration in the left arm on 24Mar2021 at 11:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis and migraines. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. Concomitant medications included hydroxychloroquine (MANUFACTURER UNKNOWN), vitamins (MANUFACTURER UNKNOWN), ethinylestradiol; ferrous fumarate; norethisterone acetate (LO LOESTRIN FE) and escitalopram oxalate (LEXAPRO), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration in the left arm on 03Mar2021 at 14:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Mar2021 at 18:00, the patient experienced muscle aches, low grade fever (100.1 for 24 hours), swollen lymph nodes, chills and headache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient underwent lab test on 09Mar2021 and 16Mar2021 which included Covid PCR test via nasal swab and the test result was negative. The patient did not receive any treatment for the events muscle aches, low grade fever (100.1 for 24 hours), swollen lymph nodes, chills and headache. The clinical outcomes of the events muscle aches, low grade fever (100.1 for 24 hours), swollen lymph nodes, chills and headache were recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Herpes zoster, Pain in extremity, SARS-CoV-2 test
Clinical narrative: Headache; sore arm; fatigue; developed shingles; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: En6206) via an unspecified route of administration in the right arm on 13Mar2021 at 12:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have allergies to medications, food, or other products. Concomitant medications received within 2 weeks of vaccination included ibuprofen (ADVIL), multi vitamin (MANUFACTURER UNKNOWN), sambucus nigra (ELDERBERRY), sertraline hydrochloride (ZOLOFT) and clarithromycin (CLARITIN), all for unknown indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: En6200) via an unspecified route of administration in right arm on 20Feb2021 at 12:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 20Mar2021 at 00:00, the patient had experienced headache, sore arm, fatigue and developed shingles 9 days after on an unknown date in Mar2021. The patient underwent lab tests and procedures, which included COVID-19 virus test via nasal swab on 23Mar2021 and the result found to be negative. The patient was treated with Valtrex for the reported events. Adverse events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events headache, sore arm, fatigue and shingles was not resolved at the time of report. No follow-up attempts are needed. No further information expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Back pain, Dizziness, Fatigue, Myalgia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 62-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE BIONTECH, Lot number: UNKNOWN) via an unknown route of administration in the left arm on 16Mar2021 at 12:30 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient was having allergy to iodine contrast dye used for MRI. The concomitant medication received by the patient within two weeks of vaccination included multivitamin (MANUFACTURER UNKNOWN) and Caltrate calcium supplement (MANUFACTURER UNKNOWN), both were taken daily for unspecified indications. The patient previously received codeine (MANUFACTURER UNKNOWN) for unspecified indication on unknown date and patient experienced allergy to it. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 18Mar2021, post 48 hours of vaccination, the patient experienced rapid heartbeat, dizziness, severe muscle and back pain, weakness, fatigue and nausea. The patient still had nausea and mild fatigue and headache 20 days after receiving vaccine (as reported). Post vaccination, the patient underwent COVID-19 nasal swab test (SARS-coV-2 test) on 25Mar2021, the result of the same was pending. The event resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment for the adverse events and was prescribed ZOFRAN for nausea. The clinical outcome of all the reported events was resolving.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, SARS-CoV-2 test, Tachycardia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 62-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER COVID-19 mRNA VACCINE BIONTECH, Lot number: UNKNOWN) via an unknown route of administration in the left arm on 16Mar2021 at 12:30 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient was having allergy to iodine contrast dye used for MRI. The concomitant medication received by the patient within two weeks of vaccination included multivitamin (MANUFACTURER UNKNOWN) and Caltrate calcium supplement (MANUFACTURER UNKNOWN), both were taken daily for unspecified indications. The patient previously received codeine (MANUFACTURER UNKNOWN) for unspecified indication on unknown date and patient experienced allergy to it. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 18Mar2021, post 48 hours of vaccination, the patient experienced rapid heartbeat, dizziness, severe muscle and back pain, weakness, fatigue and nausea. The patient still had nausea and mild fatigue and headache 20 days after receiving vaccine (as reported). Post vaccination, the patient underwent COVID-19 nasal swab test (SARS-coV-2 test) on 25Mar2021, the result of the same was pending. The event resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment for the adverse events and was prescribed ZOFRAN for nausea. The clinical outcome of all the reported events was resolving.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Therapeutic response unexpected
Clinical narrative: vision improved a week after receiving the second dose; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 15Mar2021 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included EpiLasik surgery at the age of 23 to treat short sightedness, migraine headaches and PTSD. In Oct2020, the patient developed a blurred vision all of a sudden, along with headache and confusions. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications with two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6201), via an unspecified route of administration in the left arm on 22Feb2021 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient thought her pre-existing health condition might have got worse and she was surprised when her vision improved a week on 22May2021 after receiving the second dose. She was joking that the vaccine could cure eye problems until she read a recent article which stated about 30% of the long hauling COVID patients who did not suffer the disease's severity developed blurred vision. She wondered whether Pfizer had ever followed up with their study participants (or actual vaccination outcomes) to know if they experienced any vision problems. She thought of reporting her experience anyway. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event unexpected therapeutic benefit. The clinical outcome of the event unexpected therapeutic benefit was unknown.   No follow-up attempts are possible. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Hypomenorrhoea, Menstrual disorder
Clinical narrative: lighter and shorter periods; blood has been more clotted than normal, the blood is darker brown instead of red; This is a spontaneous report from a non-contactable consumer, the patient. A 19-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 06Feb2021 (at the age of 19-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 28Feb2021 (at the age of 19-years-old); each as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, patient had not been tested for COVID-19. Since the first vaccination, on an unspecified date in Feb2021, the patient experienced lighter and shorter period. The blood was more clotted than normal and darker brown instead of red. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the lighter and shorter period and menstruation abnormal was unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Pain in extremity
Clinical narrative: Arm pain; Muscle aches; Fatigue; Headache; This is a spontaneous report received from a contactable consumer, the patient. A 45-years-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955] via an unspecified route of administration in left arm on 24Mar2021, at 09:00, (at the age of 45 years-old) as a single dose, for COVID-19 immunisation. Medical history included hypothyroidism, gastroesophageal reflux disease (GERD), migraines, eczema, environmental allergies and seasonal allergies, since unknown dates. The concomitant medications included rt (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID), esomeprazole magnesium (NEXIUM), azelastine hydrochloride; fluticasone propionate (DYMISTA), all on unknown dates taken for unknown indication and injection alave (MANUFACTURER UNKNOWN) taken for allergy. The patient previously took her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247] via an unspecified route of administration on 02Mar2021, at 10:00, (at the age of 45 years-old) as a single dose, for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 20:00, the patient had experienced local events very minor arm pain (pain in arm), systemic events minor muscle aches (muscle ache), mild fatigue (fatigue) and moderate headache (headache). The patient marked, selected not recovered because she still had mild fatigue, muscle aches and a mild (versus previously moderate) headache, but they were improving at the time of this report which was approximately 17 hours post onset. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the events. The clinical outcome of events pain in arm, muscle ache, fatigue and headache were not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Oropharyngeal discomfort
Clinical narrative: feeling faint; My throat feels a little weird; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number; ER8730) via an unspecified route of administration in the left arm on 25Mar2021 at 10:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patients medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 10:15, within few minutes of receiving the vaccine the patient felt like fainting. When notified to the staff, the patient was asked to sit in another room and started to feel better in the room. It had been in 45 minutes and then the patient was back home. It was also reported that the patient had a weird feeling in the throat which was hard to describe but he generally felt ok. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No treatment was received for the adverse events. The clinical outcome of the events feeling faint and throat discomfort were recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Insomnia, Lethargy
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via unspecified route of administration in the right arm on 23Mar2021 at 14:15 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via unspecified route of administration in the right arm on 02Mar2021 at 16:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 02:30, the patient had experienced 101.8 fever, incapacitating headache, lethargy, aches, chills, nausea and sleeplessness. The patient did not receive any treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events 101.8 fever, incapacitating headache, lethargy, aches, chills, nausea, sleeplessness was resolved with sequelae in Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via unspecified route of administration in the right arm on 23Mar2021 at 14:15 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via unspecified route of administration in the right arm on 02Mar2021 at 16:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 02:30, the patient had experienced 101.8 fever, incapacitating headache, lethargy, aches, chills, nausea and sleeplessness. The patient did not receive any treatment for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events 101.8 fever, incapacitating headache, lethargy, aches, chills, nausea, sleeplessness was resolved with sequelae in Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Pyrexia
Clinical narrative: fever; chills; headache; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EK5730), via an unspecified route of administration in the left arm on 23Mar2021 at 09:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history and Concomitant medications were not reported. The patient did not have a history of any allergies to medications, food, or other products. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021, the patient had experienced fever, chills and headache. The patient did not receive any treatment for the reported events. Adverse events did not result in any of these doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills and headache was resolved on an unknown date in Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Dizziness, Fatigue, Hyposmia
Clinical narrative: Loss of taste; Dizziness; Reduced/impaired sense of smell.; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in the right arm on 25Mar2021 at 11:15 (at the age of 53-year-old), as single dose for COVID-19 immunisation. Medical history of the patient included ruptured L4-L5 disc. The patient had a history of allergy to penicillin. Concomitant medications included hydrocodone 10mg (MANUFACTURER UNKNOWN), loratadine (CLARITIN OTC), Ibuprofen (ADVIL 400mg) and magnesium chloride (MAG); all for an unknown indication received within two weeks vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination the patient was not diagnosed with COVID-19. Since vaccination, the patient had not tested for COVID-19. On 25Mar2021 at 11:15, the patient had reduced/impaired sense of smell and on the same day at 11:17, she had dizziness within 2 minutes of shot. After 03 hours, she had experienced extreme fatigue. On 26Mar2021 after 16 hours, she had complete loss of taste. Adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the adverse events. The clinical outcome of the events dizziness, loss of taste, reduced/impaired sense of smell and extreme fatigue was not resolved at the time of report. No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Chills, Fatigue, Malaise
Clinical narrative: Lymph node pain; Axilla and chest swelling; Chest pain; Chills; Fatigue; Malaise; This is a spontaneous report from a contactable other healthcare professional, the patient. A 38-years old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 2613), via an unspecified route of administration in the left arm on 24Mar2021 at 08:00 (at the age of 38-years old) as a single dose for COVID-19 Immunisation. Medical history included as healthy patient. The patient was not allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within 2 weeks of vaccination as Concomitant medication. On 25Mar2021 at 02:15, the patient experienced lymph node, axilla and chest swelling, chest pain, chills, fatigue and malaise. The patient did not receive any treatment for event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events lymph node, axilla and chest swelling, chest pain, chills, fatigue and malaise were not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain, Rash erythematous, Rash papular, Rash pruritic
Clinical narrative: Raised red slightly itchy rash from top of neck to breasts on entire chest; Raised red slightly itchy rash from top of neck to breasts on entire chest; Raised red slightly itchy rash from top of neck to breasts on entire chest; body aches; tired; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 17Mar2021 at 14:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19 positive prior to vaccination. It was reported that the patient had no known allergies. The patient had not received any medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks, prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021 at 06:00, the patient experienced raised red, slightly itchy rash from top of neck to breasts on entire chest, body aches and tiredness. The patient did not receive any treatment for the events. The events did not result in a visit to the doctor or other healthcare professional office/clinic. The clinical outcome of raised rash, red rash, itchy rash, general body pain and tiredness was resolved on an unknown date in Mar2021. No follow-up attempts are needed. Information about lot/ batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Pain in extremity
Clinical narrative: left armpit began to significantly hurt; entire arm was sore; This is a spontaneous report received from a non-contactable consumer, the patient. A 45-year-old non pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via an unspecified route of administration in the left arm on 24Mar2021 at 10:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported.  The patient had a history of allergy to mangos. The patient received loratadine (ALAVERT) for unknown indication and birth control pill within two weeks of vaccination. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 03Mar2021 at 11:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient did not receive other vaccines within 4 weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not tested for COVID-19, since the vaccination. On 25Mar2021 at 18:00, the patient had experienced approximately 30 hours after vaccination her left armpit began significantly hurt and the entire arm was sore. In the following day morning, her pain had diminished to almost nothing. The patient did not receive any treatment for the reported events. Adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events left armpit began to significantly hurt and entire arm was sore was resolving at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Injected limb mobility decreased, Malaise, Myalgia
Clinical narrative: Severemuscle soreness radiating frominjection site; General malaise; Mild chills; Night sweats; Arm of limited use; This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 19Mar2021 at 18:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Relevant medical history included high blood pressure. No concomitant medication was reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 25Mar2021 at 11:00, after 5.5 days of the injection, the patient had severe muscle soreness radiating from injection site, to the point where arm was of limited use, mild chills, generalised malaise and night sweats and no known fever. Temperature was taken in the evening and again in the morning. The patient did not have any other COVID or flu symptoms. Therapeutic measures were taken as a result of the events that included treatment with over the counter (OTC) cold and flu medications. The adverse events did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events muscle soreness, arm of limited use, mild chills, generalised malaise and night sweats was resolving.   No follow-up attempts are possible; Information about lot number cannot be obtained.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Night sweats
Clinical narrative: Severemuscle soreness radiating frominjection site; General malaise; Mild chills; Night sweats; Arm of limited use; This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 19Mar2021 at 18:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Relevant medical history included high blood pressure. No concomitant medication was reported. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 25Mar2021 at 11:00, after 5.5 days of the injection, the patient had severe muscle soreness radiating from injection site, to the point where arm was of limited use, mild chills, generalised malaise and night sweats and no known fever. Temperature was taken in the evening and again in the morning. The patient did not have any other COVID or flu symptoms. Therapeutic measures were taken as a result of the events that included treatment with over the counter (OTC) cold and flu medications. The adverse events did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events muscle soreness, arm of limited use, mild chills, generalised malaise and night sweats was resolving.   No follow-up attempts are possible; Information about lot number cannot be obtained.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Vaccination site pain, Vaccination site reaction
Clinical narrative: Headache; Sore around injection area; Hard around injection site; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8727) via an unspecified route of administration in the left arm on 24Mar2021 at 09:30 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure, obesity and bicuspid aortic valve. The patient received unspecified medication within two weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 24Mar2021 at 16:00, the patient experienced headache, sore around injection area and hard around injection site. No therapeutic measures were taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of headache, vaccination site pain, vaccination site reaction was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Migraine
Clinical narrative: I had a migraine 2 days later; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Batch Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Mar2021 at 11:45 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The medical history included diabetes, allergies (unspecified), reflux and high blood pressure. Concomitant medications included ibuprofen (ADVIL), acetylsalicylic acid (BABY ASPIRIN), losartan potassium (LOSARTA), multivitamin (MANUFACTURER UNKNOWN) and magnesium (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 7Mar2021, 2 days later at 13:00, the patient experienced migraine. The patient had not received any treatment for migraine. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the migraine was resolved on an unspecified date.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Migraine
Clinical narrative: I got a migraine; This is a spontaneous report received from a contactable consumer, the patient. A 20-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number: UNKNOWN), via unspecified route of administration in left arm on 05Mar2021 (at the age of 20-year-old) at 11:45, as a single dose for COVID-19 immunisation. The patient medical history included asthma and allergies. The concomitant medications received by the patient within 2 weeks of vaccination included multivitamins and birth control. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 05Mar2021 at 20:00, the patient reported that she got migraine. The patient did not receive any treatments for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event migraine was resolved at the time of this report.   No follow-up attempts are possible; information about lot number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Insomnia
Clinical narrative: Mild headache at bedtime the day of vaccination.; Difficulty falling asleep; This is a spontaneous report from a contactable consumer, the parent. An 18-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via unspecified route of administration in left arm on 25Mar2021 at 13:00 (at the age of 18-year-old) as a single dose for COVID-19 immunisation. The patient medical history included kawasaki disease at the age of six years in 2008. The patient was allergic to salicylates and milk products. Concomitant medication included ibuprofen (MANUFACTURER UNKNOWN), multivitamin (MANUFACTURER UNKNOWN) and vitamin C (MANUFACTURER UNKNOWN) all were taken for unspecified indication and from unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 25Mar2021 at 21:30, the patient experienced mild headache at bedtime on the day of vaccination and difficulty falling asleep. It was reported that, the patient had mild, but less, headache upon waking. The patient did not receive any treatments for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events mild headache at bedtime and difficulty falling asleep were recovering at the time of this report.   No follow-up attempts possible. No further information expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Nausea, Vertigo
Clinical narrative: Vertigo; Dizziness; Nausea; This is a spontaneous report received from a contactable health care professional, the patient. A 57-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN206) via unspecified route of administration in arm left on 20Mar2021 (at the age of 57 years old) as a single dose, for COVID-19 immunisation. Past medical history included low thyroid and high cholesterol from an unspecified date. Concomitant medications included simvastatin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN) and venlafaxine (MANUFACTURER UNKNOWN) from an unspecified date for unknown indication received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via unspecified route of administration on left arm on 27Feb2021 at 11:00 (at the age of 57 years old) as a single dose, for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 24Mar2021, at 06:00, the patient experienced dizziness/vertigo when moving from lying down to sitting or standing, nausea at the same time. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the events vertigo, dizziness and nausea were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Influenza like illness, Musculoskeletal stiffness
Clinical narrative: Flu-like symptoms; Stiffness; Mental fogginess; Fatigue; Headache; Body ache; This is a spontaneous report from a contactable company representative, the patient. A 64-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203), via unspecified route of administration in the left arm on 17Mar2021 at 09:30 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia. The patient had no allergies to medications, food, or other products. Concomitant medications included bupropion (MANUFACTURER UNKNOWN) and gabapentin (MANUFACTURER UNKNOWN); both were taken for unknown indications from unspecified date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via unspecified route of administration on an unspecified date, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 at 20:00, the patient experienced flu-like symptoms, fatigue, stiffness, body ache, headache and mental fogginess. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events flu-like symptoms, stiffness, mental fogginess, fatigue, body ache and headache were resolved on an unknown date of Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Flu-like symptoms; Stiffness; Mental fogginess; Fatigue; Headache; Body ache; This is a spontaneous report from a contactable company representative, the patient. A 64-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203), via unspecified route of administration in the left arm on 17Mar2021 at 09:30 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia. The patient had no allergies to medications, food, or other products. Concomitant medications included bupropion (MANUFACTURER UNKNOWN) and gabapentin (MANUFACTURER UNKNOWN); both were taken for unknown indications from unspecified date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via unspecified route of administration on an unspecified date, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 at 20:00, the patient experienced flu-like symptoms, fatigue, stiffness, body ache, headache and mental fogginess. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events flu-like symptoms, stiffness, mental fogginess, fatigue, body ache and headache were resolved on an unknown date of Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Insomnia, Lacrimation increased, Nasal congestion, Pain in extremity, Rhinorrhoea
Clinical narrative: Very intense sneezing; Stuffy nose; Eyes watering; Runny nose allergy attack at midnight; Trouble sleeping all night; Arm soreness; This is a spontaneous report from a contactable other health care professional, the patient. A 33-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via unspecified route of administration in left arm, on 26Mar2021 at 13:15 (at the age of 33 years) as a single dose for COVID-19 immunisation. Medical history was not provided. The patient previously received codeine (MANUFACTURER UNKNOWN) for unspecified indication and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since having the vaccine. Concomitant medications included ambien (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN), vyvanse (MANUFACTURER UNKNOWN), doxylamine (MANUFACTURER UNKNOWN) and armour thyroid (MANUFACTURER UNKNOWN) all for unknown indications from unknown dates and unknown if ongoing. On unknown date in Mar2021, the patient experienced arm soreness, very intense sneezing, stuffy nose, eyes watering, runny nose allergy attack at midnight and trouble sleeping all night. The patient received albuterol breathing treatment, ibuprofen, zyrtec, afrin treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the events arm soreness, very intense sneezing, stuffy nose, eyes watering, runny nose allergy attack at midnight and trouble sleeping all night were not recovered at the time of report.    No follow-up attempts are needed. No further information is expected.